NCT03356795

Multicenter Trial of Chimeric Antigen Receptor-Modified T Cells (CAR-T Cells) in the Treatment of Cervical Cancer

Study Summary

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cells immunotherapy in patients who have GD2, PSMA, Muc1, Mesothelin or other markers positive cervical cancer. Another goal of the study is to learn more about the persistence and function of CAR T cells in the body.

Want to learn more about this trial?

Request More Info

Interventions

Cervical cancer-specific CAR-T cellsBIOLOGICAL
1 infusion, for 1x10\^6\~1x10\^7 cells/kg via IV

Study Locations

FacilityCityStateCountry
Shenzhen Geno-immune Medical InstituteShenzhenGuangdongChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026